Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
View Patent ↗The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
1. A cell-free, in vitro method of forming a covalent conjugate of a granulocyte colony stimulating factor (G-CSF) peptide, said peptide having the formula:
wherein
AA is a terminal or internal amino acid residue of said peptide;
X 1 —X 2 is a saccharide covalently linked to said AA, wherein
X 1 is a first glycosyl residue; and
X 2 is a second glycosyl residue covalently linked to X 1 , wherein X 1 and X 2 are selected from monosaccharyl and oligosaccharyl residues;
said method comprising:
(a) removing X 2 or a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and
(b) contacting said truncated glycan with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said truncated glycan, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer,
thereby forming said covalent conjugate of said G-CSF peptide.
2. The method of claim 1 , further comprising:
(c) prior to step (b), removing a group added to said saccharide during post-translational modification.
3. The method of claim 2 , wherein said group is a member selected from phosphate, sulfate, carboxylate and esters thereof.
4. The method of claim 1 , wherein the peptide has the formula:
wherein
Z is a member selected from O, S, NH, and a crosslinker.
5. The method of claim 1 , wherein said water-soluble polymer comprises poly(ethylene glycol).
6. The method of claim 5 , wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.
7. The method of claim 1 , wherein said peptide has the formula:
wherein
X 9 and X 10 are independently selected from monosaccharyl and oligosaccharyl residues; and
m, n and fare integers selected from 0 and 1.
8. The method of claim 1 , wherein said peptide has the formula:
wherein
X 11 and X 12 are independently selected glycosyl moieties; and
r and x are integers independently selected from 0 and 1.
9. The method of claim 8 , wherein X 11 and X 12 are (mannose) q ,
wherein
q is selected from the integers between 1 and 20, and when q is three or greater, (mannose) q is selected from linear and branched structures.
10. The method of claim 1 , wherein said peptide has the formula:
wherein
X 13 , X 14 , and X 15 are independently selected glycosyl residues; and
g, h, i, j, k, and p are independently selected from the integers 0 and 1, with the proviso that at least one of g, h, i, j, k and p is 1.
11. The method of claim 10 , wherein
X 14 and X 15 are members independently selected from GlcNAc and Sia; and i and k are independently selected from the integers 0 and 1, with the proviso that at least one of i and k is 1 and if k is 1, g, h and j are 0.
12. The method of claim 1 , wherein said peptide has the formula:
wherein
X 16 is a member selected from:
wherein
s and i are integers independently selected from 0 and 1.
13. The method of claim 1 , wherein said removing utilizes a glycosidase.
14. The method of claim 1 , wherein, following forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
15. The method of claim 5 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
16. The method of claim 1 , wherein said glycosyltransferase is CST-II.
17. A cell-free, in vitro method of forming a covalent conjugate of a G-CSF peptide, said peptide having the formula:
wherein
AA is a terminal or internal amino acid residue of said peptide;
X 1 is a glycosyl residue covalently linked to said AA, selected from monosaccharyl and oligosaccharyl residues; and
u is an integer selected from 0 and 1,
said method comprising:
contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer,
thereby forming said covalent conjugate of said G-CSF peptide.
18. The method of claim 17 , wherein said water-soluble polymer comprises poly(ethylene glycol).
19. The method of claim 18 , wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.
20. The method of claim 18 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
21. The method of claim 18 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
22. The method of claim 17 , wherein said glycosyltransferase is CST-II.
23. The method of claim 17 , wherein, following forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
24. A cell-free, in vitro method of forming a covalent conjugate between a water-soluble polymer and a glycosylated or non-glycosylated G-CSF peptide, wherein said water-soluble polymer is conjugated to said G-CSF peptide via an intact glycosyl linking group interposed between and covalently linked to both said G-CSF peptide and said water-soluble polymer, said method comprising:
contacting said G-CSF peptide with a mixture comprising a nucleotide sugar covalently linked to said water-soluble polymers, and a glycosyltransferase for which said nucleotide sugar is a substrate under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said nucleotide sugar to said G-CSF peptide, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer, thereby forming said covalent conjugate of said G-CSF peptide.
25. The method of claim 24 , wherein said glycosyl linking group is covalently attached to a glycosyl residue covalently attached to said peptide.
26. The method of claim 24 , wherein said glycosyl linking group is covalently attached to an amino acid residue of said peptide.
27. The method of claim 24 , wherein said water-soluble polymer comprises polyalkylene oxide.
28. The method of claim 27 , wherein said polyalkylene oxide is poly(ethylene glycol).
29. The method of claim 28 , wherein said poly(ethylene glycol) has a degree of polymerization of from about 1 to about 20,000.
30. The method of claim 29 , wherein said poly(ethylene) glycol has a degree of polymerization of from about 1 to about 5,000.
31. The method of claim 30 , wherein said poly(ethylene) glycol has a degree of polymerization of from about 1 to about 1,000.
32. The method of claim 24 , wherein said glycosyltransferase is selected from the group consisting of sialyltransferase, galactosyltransferase, glucosyltransferase, GalNAc transferase, GlcNAc transferase, fixcosyltransferase, and mannosyltransferase.
33. The method of claim 24 , wherein said glycosyltransferase is recombinantly produced.
34. The method of claim 33 , wherein said glycosyltransferase is a recombinant prokaryotic enzyme.
35. The method of claim 33 , wherein said glycosyltransferase is a recombinant eukaryotic enzyme.
36. The method of claim 24 , wherein said nucleotide sugar is selected from the group consisting of UDP-glycoside, CMP-glycoside, and GDP-glycoside.
37. The method of claim 36 , wherein said nucleotide sugar is selected from the group consisting of UDP-galactose, UDP-galactosamine, UDP-glucose, UDP-glucosamine, UDP-N-acetylgalactosamine, UDP-N-acetylglucosamine, GDP-mannose, GDP-fucose, CMP-sialic acid, and CMP-NeuAc.
38. The method of claim 24 , wherein said glycosylated peptide is partially deglycosylated prior to said contacting.
39. The method of claim 24 , wherein said intact glycosyl linking group is a sialic acid residue.
40. The method of claim 24 , wherein said method is performed in a cell-free environment.
41. The method of claim 24 , wherein said covalent conjugate is isolated.
42. The method of claim 41 , wherein said covalent conjugate is isolated by membrane filtration.
43. The method of claim 24 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
44. The method of claim 24 , wherein said water-soluble polymer is poly(ethylene glycol).
45. The method according to claim 24 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
46. The method of claim 44 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
47. The method of claim 44 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
48. The method of claim 24 , wherein said glycosyltransferase is CST-II.
49. A cell-free, in vitro method of forming a covalent conjugate of a G-CSF peptide, said peptide having the formula:
wherein
AA is a terminal or internal amino acid residue of said peptide,
said method comprising:
contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said amino acid residue, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer,
thereby forming said covalent conjugate of said G-CSF peptide.
50. The method of claim 49 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
51. The method of claim 49 , wherein said water-soluble polymer is poly(ethylene glycol).
52. The method of claim 51 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
53. The method of claim 51 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
54. The method of claim 49 , wherein said glycosyltransferase is CST-II.
55. The method according to claim 51 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
56. A cell-free, in vitro method of forming a covalent conjugate between a G-CSF peptide and a modifying group, wherein said modifying group is covalently attached to said G-CSF peptide through an intact glycosyl linking group, said G-CSF peptide comprising a glycosyl residue having the formula:
wherein
a, b, c, and e are members independently selected from 0 and 1;
d is 0; and
R is a water-soluble polymer,
said method comprising:
(a) contacting said G-CSF peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said G-CSF peptide, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer, such that, following said contacting, at least d is 1,
thereby forming said intact glycosyl linking group.
57. The method of claim 56 , further comprising:
(b) prior to step (a), contacting said G-CSF peptide with a sialidase under conditions appropriate to remove sialic acid from said G-CSF peptide.
58. The method of claim 56 , further comprising:
(c) prior to step (a), contacting said G-CSF peptide with a galactosyl transferase and a galactose donor under conditions appropriate to transfer said galactose to said G-CSF peptide.
59. The method of claim 56 , further comprising:
(d) contacting the product from step (a) with a moiety that reacts with said modifying group, thereby forming a conjugate between said intact glycosyl linking group and said moiety.
60. The method of claim 56 , further comprising:
(e) prior to step (a), contacting said G-CSF peptide with N-acetylgalactosamine transferase and a GalNAc donor under conditions appropriate to transfer GalNAc to said G-CSF peptide.
61. The method of claim 56 , further comprising:
(f) prior to step (a), contacting said G-CSF peptide with endo-N-acetylgalactosaminidase operating synthetically and a GalNAc donor under conditions appropriate to transfer GalNAc to said G-CSF peptide.
62. The method of claim 56 , wherein
a, b, c, and e are 0.
63. The method of claim 56 , wherein
a and e are members independently selected from 0 and 1; and
b, c, and d are 0.
64. The method of claim 56 , wherein
a, b, c, d, and e are members independently selected from 0 and 1.
65. The method of claim 56 , wherein, following forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
66. The method of claim 56 , wherein said water-soluble polymer is poly(ethylene glycol).
67. The method of claim 66 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
68. The method of claim 66 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
69. The method of claim 56 , wherein said glycosyltransferase is CST-II.
70. The method according to claim 66 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
71. A cell-free, in vitro method of forming a covalent conjugate between a G-CSF peptide and a modifying group, wherein said modifying group is covalently attached to said G-CSF peptide through an intact glycosyl linking group, said G-CSF peptide having the formula:
wherein
AA is a terminal or internal amino acid residue of said peptide;
a, b, c, and e are members independently selected from 0 and 1;
d is 0; and
R is a water-soluble polymer,
said method comprising:
(a) contacting said G-CSF peptide with a sialyltransferase and cytidine monophosphoryl sialic acid modified with poly(ethylene glycol) under conditions suitable for said sialyltransferase to transfer said sialic acid modified with poly(ethylene glycol) to said G-CSF peptide such that, following said contacting, at least d is 1.
72. The method according to claim 71 , wherein
said glycosyltransferase is ST3Gal3 and said cytidine monophosphoryl sialic acid modified with poly(ethylene glycol) has the formula:
wherein
R is a poly(ethylene glycol) moiety.
73. The method of claim 71 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
74. The method according to claim 71 , wherein said water-soluble polymer is poly(ethylene glycol).
75. The method according to claim 74 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
76. The method of claim 74 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
77. The method of claim 74 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
78. A cell-free in vitro method of forming a covalent conjugate of a G-CSF peptide, said peptide having the formula:
wherein
r, s, and tare integers independently selected from 0 and 1,
said method comprising:
(a) contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer, thereby forming said covalent conjugate of said G-CSF peptide.
79. The method of claim 78 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
80. The method according to claim 78 , wherein said water-soluble polymer is poly(ethylene glycol).
81. The method according to claim 80 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
82. The method of claim 80 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
83. The method of claim 80 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
84. The method of claim 78 , wherein said glycosyltransferase is CST-II.
85. A cell-free, in vitro method of forming a covalent conjugate of a G-CSF peptide, said peptide having the formula:
wherein
AA is a terminal or internal amino acid residue of said peptide;
X 1 —X 2 is a saccharide covalently linked to said AA, wherein
X 1 is a first glycosyl residue; and
X 2 is a second glycosyl residue covalently linked to X 1 , wherein X 1 and X 2 are selected from monosaccharyl and oligosaccharyl residues;
said method comprising:
(a) removing X 1 and X 2 , exposing said AA; and
(b) contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer,
thereby forming said covalent conjugate of said G-CSF peptide.
86. The method of claim 85 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
87. The method according to claim 85 , wherein said water-soluble polymer is poly(ethylene glycol).
88. The method according to claim 87 , wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse.
89. The method of claim 87 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
90. The method of claim 87 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
91. The method of claim 85 , wherein said glycosyltransferase is CST-II.
92. A cell-free, in vitro method of forming a covalent conjugate of a G-CSF peptide, said peptide having the formula:
wherein
X 3 , x 4 , X 5 , X 6 , x 7 , and X 17 are independently selected from monosaccharyl and oligosaccharyl residues; and
a, b, c, d, e and x are independently selected from the integers 0, 1 and 2, with the proviso that at least one member selected from a, b, c, d, and e and x is 1 or 2; said method comprising:
(a) removing at least one of X 3 , X 4 , X 5 , X 6 , X 7 , or X 17 , or a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and
(b) contacting said truncated glycan with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said truncated glycan, wherein said modified sugar moiety comprises at least one modifying group which is a water-soluble polymer,
thereby forming said covalent conjugate of said G-CSF peptide.
93. The method of claim 92 , wherein said removing of step (a) produces a truncated glycan in which a, b, c, e and x are each 0.
94. The method of claim 92 , wherein X 3 , X 5 , and X 7 , are selected from the group consisting of (mannose) z and (mannose) z -(X 8 ) y
wherein
X 8 is a glycosyl moiety selected from mono- and oligo-saccharides;
y is an integer selected from 0 and 1; and
z is an integer between 1 and 20, wherein
when z is 3 or greater, (mannose) z is selected from linear and branched structures.
95. The method of claim 92 , wherein X 4 is selected from the group consisting of GlcNAc and xylose.
96. The method of claim 92 , wherein X 3 , X 5 , and X 7 are (mannose) u , wherein
u is selected from the integers between 1 and 20, and when u is 3 or greater, (mannose) u is selected from linear and branched structures.
97. The method of claim 92 , wherein, following said forming said covalent conjugate, said G-CSF peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said G-CSF peptide.
98. The method of claim 92 , wherein said water-soluble polymer comprises poly(ethylene glycol).
99. The method of claim 98 , wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.
100. The method of claim 98 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).
101. The method of claim 98 , wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol).
102. The method of claim 92 , wherein said glycosyltransferase is CST-II.
103. The method of claim 5 , wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).